Investors Buy Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the recipient of some unusual options trading on Wednesday. Traders bought 1,002 put options on the stock. This is an increase of approximately 1,791% compared to the typical daily volume of 53 put options.

Maravai LifeSciences Stock Performance

NASDAQ MRVI opened at $4.37 on Thursday. The company has a debt-to-equity ratio of 0.72, a current ratio of 5.91 and a quick ratio of 5.69. Maravai LifeSciences has a 1 year low of $1.95 and a 1 year high of $4.99. The company has a market capitalization of $1.12 billion, a PE ratio of -6.15 and a beta of 0.62. The company has a fifty day moving average of $3.43 and a two-hundred day moving average of $3.43.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.06. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. The company had revenue of $65.84 million during the quarter, compared to the consensus estimate of $53.00 million. As a group, analysts expect that Maravai LifeSciences will post -0.26 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MRVI has been the topic of several recent analyst reports. Wells Fargo & Company increased their target price on Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a report on Friday, May 8th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $6.00 target price on shares of Maravai LifeSciences in a report on Friday, May 8th. Finally, Wall Street Zen raised Maravai LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Maravai LifeSciences presently has a consensus rating of “Moderate Buy” and an average price target of $5.50.

Institutional Investors Weigh In On Maravai LifeSciences

Several hedge funds have recently made changes to their positions in the business. Tejara Capital Ltd grew its holdings in shares of Maravai LifeSciences by 26.4% during the third quarter. Tejara Capital Ltd now owns 2,453,441 shares of the company’s stock worth $7,041,000 after buying an additional 511,992 shares during the last quarter. Monaco Asset Management SAM grew its holdings in shares of Maravai LifeSciences by 315.0% during the third quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock worth $10,494,000 after buying an additional 2,775,372 shares during the last quarter. First Eagle Investment Management LLC purchased a new position in shares of Maravai LifeSciences during the third quarter worth about $1,294,000. Royce & Associates LP grew its holdings in shares of Maravai LifeSciences by 38.0% during the third quarter. Royce & Associates LP now owns 1,761,764 shares of the company’s stock worth $5,056,000 after buying an additional 484,908 shares during the last quarter. Finally, General American Investors Co. Inc. purchased a new position in shares of Maravai LifeSciences during the third quarter worth about $391,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.